(17), EGFR mutation was found in 29 of 64 tumours from 35 patients with synchronous MPLAs, most significantly the EGFR 19del and EGFR L858R mutation, identified sMPLA dependence on this pathway for growth and proliferation and appeared to sensitize tumours to the effects of a small molecule Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). Here, EGFR is linked to neoplasm.